PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Stock data | 2023 | Change |
---|---|---|
Price | $3.39 | N/A |
Market Cap | $11.50M | N/A |
Shares Outstanding | 3.40M | 2.88% |
Employees | 65.00 | N/A |
Shareholder Equity | 1.51B | 82.87% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.03 | N/A |
P/S Ratio | 0.79 | N/A |
P/B Ratio | 0.01 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0022 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $14.47M | N/A |
Earnings | $3.36M | N/A |
EPS | 97.29 | N/A |
Earnings Yield | 28.73 | N/A |
Gross Margin | 0.7328 | N/A |
Operating Margin | 0.2394 | N/A |
Net income margin | 0.2323 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $20.56M | N/A |
Total Debt | $7.70M | N/A |
Cash on Hand | $10.60M | N/A |
Debt to Equity | 0.0068 | -43.36% |
Cash to Debt | $1.38 | 7.88% |
Current Ratio | $1.78 | -57.83% |